Janux Therapeutics, Inc. (JANX) stock
JANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3031% below fair value
$11.37−0.13 (-1.09%)
Close on Nov 13, 2026Market cap $695.13MP/E –Yield –
Janux Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Janux Therapeutics's total assets was $983.66M at Sep 30, 2026. For fiscal 2025 it was $1.00B, down 5.6% from the year before. The highest annual figure on record is $1.06B in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.00B | -5.6% |
| FY2024 | Dec 31, 2024 | $1.06B | +179.0% |
| FY2023 | Dec 31, 2023 | $380.41M | +4.5% |
| FY2022 | Dec 31, 2022 | $364.01M | -4.2% |
| FY2021 | Dec 31, 2021 | $379.82M | +2242.1% |
| FY2020 | Dec 31, 2020 | $16.22M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $983.66M | -4.0% |
| Q2 FY2026 | Jun 30, 2026 | $1.01B | -2.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.03B | -2.1% |
| Q4 FY2025 | Dec 31, 2025 | $1.00B | -5.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.02B | +47.4% |
| Q2 FY2025 | Jun 30, 2025 | $1.03B | +49.3% |
| Q1 FY2025 | Mar 31, 2025 | $1.05B | +52.5% |
| Q4 FY2024 | Dec 31, 2024 | $1.06B | +179.0% |
| Q3 FY2024 | Sep 30, 2024 | $695.02M | +79.7% |
| Q2 FY2024 | Jun 30, 2024 | $691.41M | +102.5% |
| Q1 FY2024 | Mar 31, 2024 | $688.98M | +95.2% |
| Q4 FY2023 | Dec 31, 2023 | $380.41M | +4.5% |
| Q3 FY2023 | Sep 30, 2023 | $386.85M | +3.0% |
| Q2 FY2023 | Jun 30, 2023 | $341.50M | -11.4% |
| Q1 FY2023 | Mar 31, 2023 | $352.96M | -4.2% |
| Q4 FY2022 | Dec 31, 2022 | $364.01M | -4.2% |
| Q3 FY2022 | Sep 30, 2022 | $375.76M | -3.9% |
| Q2 FY2022 | Jun 30, 2022 | $385.37M | -2.9% |
| Q1 FY2022 | Mar 31, 2022 | $368.60M | +2172.9% |
| Q4 FY2021 | Dec 31, 2021 | $379.82M | – |
| Q3 FY2021 | Sep 30, 2021 | $391.08M | – |
| Q2 FY2021 | Jun 30, 2021 | $396.82M | – |
| Q4 FY2020 | Dec 31, 2020 | $16.22M | – |
See a number that looks wrong?